NasdaqGM:ANIPPharmaceuticals
Is Record 2025 Sales And 2026 Guidance Past US$1 Billion Altering The Investment Case For ANI Pharmaceuticals (ANIP)?
ANI Pharmaceuticals recently reported record 2025 revenue of US$883.4 million, driven largely by strong growth in its Rare Disease segment and Cortrophin Gel, while an executive share sale on March 11, 2026 drew investor attention.
The company’s guidance for more than US$1.00 billion in 2026 revenue highlights how Rare Disease therapies are becoming an increasingly central pillar of its business model.
We’ll now examine how ANI Pharmaceuticals’ push past US$1.00 billion in guided 2026...